Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16563661rdf:typepubmed:Citationlld:pubmed
pubmed-article:16563661lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:16563661lifeskim:mentionsumls-concept:C1335754lld:lifeskim
pubmed-article:16563661lifeskim:mentionsumls-concept:C0392920lld:lifeskim
pubmed-article:16563661lifeskim:mentionsumls-concept:C0012899lld:lifeskim
pubmed-article:16563661lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:16563661lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:16563661pubmed:issue4lld:pubmed
pubmed-article:16563661pubmed:dateCreated2006-6-6lld:pubmed
pubmed-article:16563661pubmed:abstractTextA line of investigation in the search for sensitizing tumor cells to chemotherapy or radiotherapy relies on the selection of DNA repair inhibitors. In the area of DNA repair mechanisms, DNA-dependent protein kinase (DNA-PK) represents a key complex. Indeed DNA-PK is involved in the non-homologous end joining (NHEJ) process that corresponds to the major activity responsible for cell survival after ionizing radiation or chemotherapeutic treatment producing DNA double strand breaks. DNA-PK belongs to the PI3-K related kinase family and specific inhibitors have been recently selected and evaluated as radio- and chemo-sensitizers. These drugs, along with other ways to inhibit the DSBs repair process, are presented and discussed.lld:pubmed
pubmed-article:16563661pubmed:languageenglld:pubmed
pubmed-article:16563661pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16563661pubmed:citationSubsetIMlld:pubmed
pubmed-article:16563661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16563661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16563661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16563661pubmed:statusMEDLINElld:pubmed
pubmed-article:16563661pubmed:monthMaylld:pubmed
pubmed-article:16563661pubmed:issn0369-8114lld:pubmed
pubmed-article:16563661pubmed:authorpubmed-author:SallesBBlld:pubmed
pubmed-article:16563661pubmed:authorpubmed-author:MullerCClld:pubmed
pubmed-article:16563661pubmed:authorpubmed-author:GRAYLLJrlld:pubmed
pubmed-article:16563661pubmed:authorpubmed-author:CalsouPPlld:pubmed
pubmed-article:16563661pubmed:issnTypePrintlld:pubmed
pubmed-article:16563661pubmed:volume54lld:pubmed
pubmed-article:16563661pubmed:ownerNLMlld:pubmed
pubmed-article:16563661pubmed:authorsCompleteYlld:pubmed
pubmed-article:16563661pubmed:pagination185-93lld:pubmed
pubmed-article:16563661pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:16563661pubmed:meshHeadingpubmed-meshheading:16563661...lld:pubmed
pubmed-article:16563661pubmed:meshHeadingpubmed-meshheading:16563661...lld:pubmed
pubmed-article:16563661pubmed:meshHeadingpubmed-meshheading:16563661...lld:pubmed
pubmed-article:16563661pubmed:meshHeadingpubmed-meshheading:16563661...lld:pubmed
pubmed-article:16563661pubmed:meshHeadingpubmed-meshheading:16563661...lld:pubmed
pubmed-article:16563661pubmed:meshHeadingpubmed-meshheading:16563661...lld:pubmed
pubmed-article:16563661pubmed:year2006lld:pubmed
pubmed-article:16563661pubmed:articleTitleThe DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy.lld:pubmed
pubmed-article:16563661pubmed:affiliationInstitut de Pharmacologie et Biologie Structurale (IPBS) UMR CNRS 5089, Toulouse, France. bernard.salles@ipbs.frlld:pubmed
pubmed-article:16563661pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16563661pubmed:publicationTypeReviewlld:pubmed
pubmed-article:16563661pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16563661lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16563661lld:pubmed